droxidopa

Ligand id: 7391

Name: droxidopa

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 5
Rotatable bonds 3
Topological polar surface area 124.01
Molecular weight 213.06
XLogP -3.14
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Approved to treat neurogenic orthostatic hypotension (NOH), a condition characterised by a chronic and debilitating drop in blood pressure when rising to a standing position. NOH may be associated with other conditions including multiple system atrophy (MSA), familial amyloid polyneuropathy (FAP), and Parkinson's disease (PD).
Mechanism Of Action and Pharmacodynamic Effects
Droxidopa is a synthetic amino acid precursor of the sympathetic neurotransmitter noradrenaline (norepinephrine) [1]. Noradrenaline is a potent vasoconstrictor acting in the sympathetic nervous system to regulate cardiovascular activity. The enzyme aromatic L-amino acid decarboxylase (aka dopa decarboxylase, DDC; P20711) is responsible for decarboxylation of the prodrug. Drug treatment results in increased blood pressure and improved orthostatic tolerance.